Johnstown, PA (PRWEB) July 11, 2012
EP Global Communications, Inc. (the Company) , (Pink Sheets: EPGL.PK), is pleased to announce the appointment of Corey W. Hunter M.D. to the position of Company Medical Director and Chairman of the Scientific Advisory Board. Dr. Hunter was pivotal in conducting early research on the MPDD device. Along with NYU physicians, Michel Dubois M.D. and Shengping Zou M.D., Dr. Hunter headed the team which published one of the first research studies showing significant improvement for the detection of pain caused by muscles, using the MPDD device versus traditional manual pressure (MP) for the diagnosis and treatment Myofascial Pain Syndrome which can include chronic back pain, neck pain, migraine, fybromyalgia and more. These findings greatly contributed to the early progress of the MPDD development and its subsequent FDA 510k clearance and patent awards.
Corey W. Hunter, MD is based in New York City. He completed his residency in physical medicine and rehabilitation at NYU Langone Medical Center and a fellowship in pain medicine at Weill Cornell Medical College. Dr. Hunter's specialties include pain diagnosis and treatment, disorders of the spine and peripheral nervous system, with a special interest in advanced interventional techniques and minimally invasive spinal procedures.
As Company Medical Director, Dr. Hunter's exceptional knowledge and expertise will guide the MPDD device to a successful launch in the U.S. and international healthcare markets. Shareholders should expect announcements about other key management appointments in the near future, including additional key individuals with expertise in business management and medical technology.
In other Company news, the 10:1 reverse split is on track to take effect shortly. Over the past several days there have been some unexpected delays in the collection and filing of requisite Company documents due to restructuring of the Company. These documents are presently being completed and filed as expeditiously as possible. The restructuring partners are aware that shareholders are interested and anticipating when this reverse split will occur. To that end, the Company will attempt to give shareholders at least 24 hours notice, as soon as it is informed of the exact date.
The Company wishes to emphasize to shareholders that once the 10:1 reverse split occurs, the freely trading common shares will reduce sharply to approximately 499 million shares. The remaining majority of authorized common shares will be issued to the restructuring partners and will be restricted shares under the 1933 Securities Act. All the toxic debt has now been eliminated and there will be no unscrupulous dumping of shares into the market as service to debt ever again. The restructuring partners will never consider such a financing arrangement in the future and will not allow that predicament to occur to the Company or its shareholders again. In contrast, the restructuring partners of the Company are committed to growing the Company and shareholder value significantly for the long term.
About EP Global Communications, Inc.
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.